Adverse effect · Mazdutide

How common is GI side effects with Mazdutide?

A
Grade A — established in humansPhase 3 · effect size: moderate · adverse
Short answerEstablished in humans. Phase 3 point the same way: a moderate effect. Nausea, diarrhoea and vomiting were the most frequent adverse events, mostly mild to moderate; discontinuation for adverse events 2.9% versus 0% in GLORY-2.

What the studies show

Nausea, diarrhoea and vomiting were the most frequent adverse events, mostly mild to moderate; discontinuation for adverse events 2.9% versus 0% in GLORY-2.

Several well-run randomised trials in people, pointing the same way. You can plan around this. It still says nothing about whether the effect is worth the side effects for you.

  1. 1
    Ji L, et al. Once-weekly mazdutide in Chinese adults with obesity or overweight (GLORY-1).N Engl J Med, 2025; DOI 10.1056/NEJMoa2411528610 adults, 48 weeks.
  2. 2
    Innovent. Mazdutide 9 mg achieves up to 20.1% weight loss in Chinese adults with obesity (GLORY-2 topline).Press release, 19 Nov 2025462 adults, 60 weeks; topline, not yet peer-reviewed.

In context

Mazdutide is a once-weekly GLP-1/glucagon dual agonist developed by Innovent with Lilly. In the 610-person GLORY-1 trial, published in the New England Journal of Medicine in May 2025, it produced 14.8% weight loss at 48 weeks on 6 mg against 0.5% on placebo; a 9 mg dose reached 18.6% at 60 weeks in GLORY-2. China's regulator approved it for chronic weight management on 27 June 2025 and later for type 2 diabetes. It is not approved in the US, EU or UK.

Mazdutide is approved in china only. Legal status differs by country — see the regulation section or the jurisdiction pages.

Questions

Is Mazdutide proven to cause GI side effects?
Yes, as far as human trials can show it: Phase 3. LYO grades this outcome A.
What studies are behind the grade?
Nausea, diarrhoea and vomiting were the most frequent adverse events, mostly mild to moderate; discontinuation for adverse events 2.9% versus 0% in GLORY-2.
Is Mazdutide approved for this?
Mazdutide is an approved medicine (Approved in China only); whether this particular outcome is a licensed indication is stated on the compound page's regulation section.

Other outcomes for Mazdutide

Reviewed 3 September 2026. Grades count human evidence only; see how LYO grades. Not medical advice. Correct this page →